Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07256210 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

Name: Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation — clinical trial record (NCT07256210)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Started2025-05-09

View on ClinicalTrials.gov ↗

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

17 trials monitored

See all monitored trials

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

Acute Lymphoblastic Leukemia (ALL)

873 trials monitored

See 52 trials at risk

This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.

Trial Details

NCT Number	NCT07256210
Lead Sponsor	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions	Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
Enrollment	15 participants
Start Date	2025-05-09
Primary Completion	2026-10 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-01